VistaGen Therapeutics, Inc. (VTGN): Price and Financial Metrics

VistaGen Therapeutics, Inc. (VTGN): $0.91

0.03 (+3.84%)

POWR Rating

Component Grades













Add VTGN to Watchlist
Sign Up

Industry: Biotech



in industry


  • Sentiment is the dimension where VTGN ranks best; there it ranks ahead of 84.8% of US stocks.
  • The strongest trend for VTGN is in Value, which has been heading down over the past 179 days.
  • VTGN's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

VTGN Stock Summary

  • VistaGen Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 7.77% of US listed stocks.
  • With a price/sales ratio of 161.19, VistaGen Therapeutics Inc has a higher such ratio than 98.3% of stocks in our set.
  • As for revenue growth, note that VTGN's revenue has grown 133.46% over the past 12 months; that beats the revenue growth of 93.95% of US companies in our set.
  • Stocks that are quantitatively similar to VTGN, based on their financial statements, market capitalization, and price volatility, are VBLT, GNCA, GERN, STTK, and AYLA.
  • Visit VTGN's SEC page to see the company's official filings. To visit the company's web site, go to

VTGN Valuation Summary

  • VTGN's price/sales ratio is 406.1; this is 3477.97% higher than that of the median Healthcare stock.
  • VTGN's price/earnings ratio has moved down 12.3 over the prior 65 months.
  • Over the past 65 months, VTGN's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for VTGN.

Stock Date P/S P/B P/E EV/EBIT
VTGN 2021-08-31 406.1 6.8 -12.5 -21.8
VTGN 2021-08-30 392.7 6.6 -12.1 -21.0
VTGN 2021-08-27 407.5 6.9 -12.5 -21.9
VTGN 2021-08-26 384.8 6.5 -11.8 -20.5
VTGN 2021-08-25 396.7 6.7 -12.2 -21.2
VTGN 2021-08-24 396.7 6.7 -12.2 -21.2

VTGN Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 2957.25%.
  • The 4 year net cashflow from operations growth rate now stands at -227.69%.
  • Its 2 year net income to common stockholders growth rate is now at -41.49%.
Over the past 52 months, VTGN's revenue has gone up $261,900.

The table below shows VTGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 1.5119 -34.9499 -61.579
2021-09-30 1.4676 -27.893 -56.4881
2021-06-30 1.4436 -15.4397 -46.9635
2021-03-31 1.0895 -12.0735 -42.3198
2020-12-31 0.6476 -9.3708 -16.3521
2020-09-30 0.334 -8.6618 -16.9831

VTGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VTGN has a Quality Grade of C, ranking ahead of 36.05% of graded US stocks.
  • VTGN's asset turnover comes in at 0.017 -- ranking 376th of 682 Pharmaceutical Products stocks.
  • SAGE, SVRA, and EDIT are the stocks whose asset turnover ratios are most correlated with VTGN.

The table below shows VTGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 1 -4.522
2021-03-31 0.018 1 -3.130
2020-12-31 0.018 1 -2.501
2020-09-30 0.036 1 -2.651
2020-06-30 0.000 NA -3.134
2020-03-31 0.000 NA -3.789

VTGN Price Target

For more insight on analysts targets of VTGN, see our VTGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.00 Average Broker Recommendation 1.12 (Strong Buy)

VTGN Stock Price Chart Interactive Chart >

Price chart for VTGN

VTGN Price/Volume Stats

Current price $0.91 52-week high $3.32
Prev. close $0.88 52-week low $0.83
Day low $0.88 Volume 1,996,000
Day high $1.01 Avg. volume 1,367,687
50-day MA $1.09 Dividend yield N/A
200-day MA $1.65 Market Cap 187.75M

VistaGen Therapeutics, Inc. (VTGN) Company Bio

VistaGen Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops products for patients with diseases and disorders involving the central nervous system. VistaGen Therapeutics serves customers in the United States.

VTGN Latest News Stream

Event/Time News Detail
Loading, please wait...

VTGN Latest Social Stream

Loading social stream, please wait...

View Full VTGN Social Stream

Latest VTGN News From Around the Web

Below are the latest news stories about VistaGen Therapeutics Inc that investors may wish to consider to help them evaluate VTGN as an investment opportunity.

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 37.50% and 8.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 10, 2022

VistaGen Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update

Advancing late-stage PH94B clinical program, including: Progress towards topline data readouts for PALISADE-1 and PALISADE-2 Phase 3 trials designed to evaluate PH94B in social anxiety disorder (SAD) that are expected in mid-2022 and second half 2022, respectively;PALISADE Long-term Safety Study and exploratory Phase 2A trial in adjustment disorder with anxiety (AjDA) initiated; and Preparation for clinical development in additional anxiety indications underway. PH10 Phase 2B clinical program in

Yahoo | February 10, 2022

VistaGen Therapeutics to Report Fiscal Year 2022 Third Quarter Financial Results on February 10, 2022

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, will host a conference call and webcast on Thursday, February 10, 2022 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report its financial results for its fi

Yahoo | February 7, 2022

Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline

VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 3, 2022

Analysts Expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Will Announce Quarterly Sales of $330,000.00

Equities research analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to announce $330,000.00 in sales for the current quarter, Zacks reports. Two analysts have made estimates for VistaGen Therapeutics earnings, with estimates ranging from $300,000.00 to $360,000.00. VistaGen Therapeutics reported sales of $310,000.00 during the same quarter last year, which would suggest a positive year over year []

Dakota Financial News | December 4, 2021

Read More 'VTGN' Stories Here

VTGN Price Returns

1-mo -14.95%
3-mo -33.09%
6-mo -48.30%
1-year -71.74%
3-year 34.20%
5-year -49.72%
YTD -53.33%
2021 0.52%
2020 181.28%
2019 -54.02%
2018 35.14%
2017 -70.24%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4304 seconds.